← Back to screener

ALNYLAM PHARMACEUTICALS, INC. ALNY

Rank #1699 · Nasdaq · $21.9B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
44.0
P/E
-49.7
P/B
-138.30
ROE
278.2%
Op. Margin
-15.4%
Debt Ratio
-2637%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -49.7x, P/B -138.30x. Ranks in the top 84% of the universe.

Profitability ★★★☆☆
Average

ROE 278.2%. Ranks in the top 41% of the universe.

Safety ★★★★★
Excellent

Debt ratio -2637%. Ranks in the top 1% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 76.2% year over year. Ranks in the top 5% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.2B–116
2012–$-0.0B$-0.0B$0.2B–92
2013–$-0.1B$-0.1B$0.2B–97
2014–$-0.1B$-0.1B$0.1B–127
2015–$-0.1B$-0.1B$0.1B–107
2016–$-0.4B$-0.4B$0.3B–45
2017–$-0.3B$-0.3B$0.9B–37
2018$0.0B$-0.4B$-0.4B$1.3B-900.318
2019$0.1B$-0.5B$-0.5B$0.9B-556.230
2020$0.0B$-0.8B$-0.8B$1.8B-28092.254
2021$0.2B$-0.9B$-0.9B$1.3B-427.5184
2022$0.5B$-0.8B$-0.9B$1.4B-168.1212
2023$0.8B$-0.7B$-0.9B$1.0B-83.9365
2024$1.0B$-0.8B$-1.1B$0.6B-75.7689
2025$1.8B$-0.3B$-0.4B$-0.2B-15.4-2637

← See the full screener